Zacks Investment Research Lowers Yield10 Bioscience (NASDAQ:YTEN) to Sell

Zacks Investment Research downgraded shares of Yield10 Bioscience (NASDAQ:YTEN) from a hold rating to a sell rating in a research report report published on Saturday morning, Zacks.com reports.

According to Zacks, “Yield10 Bioscience, Inc. is an agricultural bioscience company. It focuses on the development of disruptive technologies for improvement in crop yield to enhance global food security. The company is working on new approaches, to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism for better production. It operates primarily in Saskatoon, Saskatchewan, Canada. Yield10 Bioscience, Inc., formerly known as Metabolix, Inc., is based in Woburn, Massachusetts. “

Several other analysts also recently commented on YTEN. National Securities restated a buy rating and issued a $5.00 price target on shares of Yield10 Bioscience in a research note on Tuesday, August 13th. Aegis restated a buy rating and issued a $2.00 price target on shares of Yield10 Bioscience in a research note on Tuesday, August 13th. Finally, Maxim Group restated a buy rating and issued a $3.00 price target on shares of Yield10 Bioscience in a research note on Friday, May 31st.

YTEN stock opened at $0.94 on Friday. Yield10 Bioscience has a twelve month low of $0.68 and a twelve month high of $1.77. The company has a quick ratio of 3.33, a current ratio of 3.33 and a debt-to-equity ratio of 1.17. The firm has a market cap of $11.53 million, a PE ratio of -1.02 and a beta of 3.21. The business has a 50 day moving average of $0.92 and a 200 day moving average of $1.02.

Yield10 Bioscience (NASDAQ:YTEN) last posted its quarterly earnings data on Monday, August 12th. The specialty chemicals company reported ($0.15) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.06. Yield10 Bioscience had a negative return on equity of 145.61% and a negative net margin of 1,320.21%. The company had revenue of $0.32 million during the quarter. On average, research analysts expect that Yield10 Bioscience will post -0.66 earnings per share for the current fiscal year.

An institutional investor recently raised its position in Yield10 Bioscience stock. Renaissance Technologies LLC lifted its position in Yield10 Bioscience Inc (NASDAQ:YTEN) by 9.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 478,176 shares of the specialty chemicals company’s stock after purchasing an additional 41,500 shares during the quarter. Renaissance Technologies LLC owned about 3.83% of Yield10 Bioscience worth $463,000 at the end of the most recent reporting period. 7.80% of the stock is owned by hedge funds and other institutional investors.

About Yield10 Bioscience

Yield10 Bioscience, Inc, an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States and Canada. The company, through its Smart Carbon Grid for Crops and T3 platforms, is involved in improving fundamental crop yield through enhanced photosynthetic carbon capture, as well as increased carbon utilization efficiency to increase seed yield.

Further Reading: What Factors Can Affect Return on Equity?

Get a free copy of the Zacks research report on Yield10 Bioscience (YTEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Yield10 Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yield10 Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.